BY CANTON: LAB-CONFIRMED CASES IN the past fortnight per 100K population—down. Worst still in Uri, also Appenzell Innerrhoden. Dark end of scale down from 529 to 446.
BY CANTON: LAB-CONFIRMED HOSPITALISATION in the past fortnight per 100K population—Improving, down from 6.04 to 4.82. Worse in and around Uri, so dark end of scale up from 27 to 30
One way to compromise between high protective tariffs and market access
⬇️
Low or zero duty for limited quantities (quotas). Beyond that high tariffs kick in—not “phased in” @nicholaswatt@BBCr4today
1/6
That way the two tariff levels allow some market access but keep it limited so some protection remains for local producers
It’s not the only way to compromise. Another: set a medium-level tariff for all imports of that product. But quantities would depend on supply & demand
2/6
Advantage of a tariff quota: the limit of low/zero duty imports is known. With a medium tariff it is not known.
Disadvantages: complexity in the way the govt hands out the quota among importers, and “quota rent”—benefits, sometimes huge, to those with a share of the quota
Pfizer/BioNTech, Moderna mRNA vaccinations ongoing. J&J approved, not ordered. Supply picking up. Not yet approved: AstraZeneca, Curevac and Novavax. Switzerland has ordered over 30m doses for 8m people